Managed Healthcare Executive August 5, 2024
A new study conducted by researchers at the United Therapeutics Corporation in Durham, NC, looked to characterize PH-ILD disease burden by analyzing healthcare resource utilization (HCRU) and cost data.
Pulmonary hypertension due to interstitial lung disease (PH-ILD) has long been connected to high rates of respiratory failure and death.
A new study conducted by researchers at the United Therapeutics Corporation in Durham, NC, looked to characterize PH-ILD disease burden by analyzing healthcare resource utilization (HCRU) and cost data.
The study, published July 11, 2024 in BMC Pulmonary Medicine, discovered the hospitalization among patients with PH-ILD more than doubled over a 2-year period; additionally, total health care costs also more than doubled after the same 2 years.
“Group 3 PH represents...
Today's Sponsors
Today's Sponsor